CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.
- What Goes Into Restarting A Shelved Orphan Drug Candidate?
- A Much-Improved Approach For Understanding And Managing Safety Risks
- Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission
- CSV Assumes The AI System Sits Still — It Doesn't.
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
- Combination Cell Therapy's Clinical Success Hinges On Manufacturability
- Are Biopharma Companies Outsourcing Their Ability To Think?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1634050535 data, logistics]( "Expert Insights In Navigating CGT's Complex Supply Chain")
Expert Insights In Navigating CGT's Complex Supply ChainExamine insights shared during Cencora's ThinkLive Cell and Gene Therapy Summit 2024 that shed light on the challenges and opportunities in navigating the complexities of the cell and gene supply chain.
-
![GettyImages-1759287088 patient nurse consultation]( "Guiding GLP-1 Participants Through The Challenge Of Retention")
Guiding GLP-1 Participants Through The Challenge Of RetentionLearn how remote lifestyle coaching can combat high dropout rates in metabolic research by offering the support participants need to maintain adherence and ensure data integrity.
-
![GettyImages-1382353763-computer-medical-documents-review]( "Building A High-Quality IND From Scratch With Strategic Gap Analysis")
Building A High-Quality IND From Scratch With Strategic Gap AnalysisA biotech sponsor lacking in-house regulatory expertise engaged a partner to obtain strategic regulatory review, medical writing, project management, and electronic publishing (eCTD).
-
![GettyImages-1337678825-assay-well-plate-cell-culture]( "Matrigel Dome Assay And Drug Screening Of Colorectal Cancer Organoids")
Matrigel Dome Assay And Drug Screening Of Colorectal Cancer OrganoidsUsing CRC organoids and bioprinting, explore the automation of dome assays to evaluate drug responses and delve into the insights from image-based end-point assays on the efficacy of anti-cancer treatments.
-
![Thermo Fisher - SUB DynaDrive]( "A Paradigm Shift From Glass Benchtop Bioreactors")
A Paradigm Shift From Glass Benchtop BioreactorsLearn how a bench-scale single-use bioreactor offers process development advantages over traditional glass systems, including higher efficiency, increased productivity, and enhanced sustainability.
-
![GettyImages-1269813787 mobile visit nurse]( "Enhance Access And Improve Retention In Rare Disease Trials With HTS")
Enhance Access And Improve Retention In Rare Disease Trials With HTSHome Trial Support (HTS) provides a solution to improving participant recruitment and retention during musculoskeletal studies.
-
![GettyImages-1213680755-scientist-gloves-assay-cell-culture]( "Bispecific T- Cell Engager (BiTE) Screening, Automated Pipeline")
Bispecific T- Cell Engager (BiTE) Screening, Automated PipelineView automated, high‑throughput BiTE screening in mammalian cells, enabling rapid discovery of efficacious variants through precise genomic integration and scalable workflows.
-
![GettyImages-2166558808-data-gene-dna-genomic]( "Partner Case Study: Accelerating Gene Editing Manufacturing")
Partner Case Study: Accelerating Gene Editing ManufacturingBeam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.
-
![Pipette With Cell Culture Plate-GettyImages-520238063]( "Cytokines For Ex Vivo Cell Culture")
Cytokines For Ex Vivo Cell CultureComparable T cell expansion and function between cytokine sources were demonstrated. Generated CAR-T cells showed robust cytotoxicity and lower exhaustion markers.
-
![GettyImages-1309776504-viral-inspection-laboratory-scientists]( "Accelerated LVV Manufacturing Enabled By Platform Excellence")
Accelerated LVV Manufacturing Enabled By Platform ExcellenceDiscover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.
NEWSLETTER ARCHIVE
- 08.21.26 -- Smarter Workflows For Cell & Gene Production
- 08.21.26 -- Rewriting The Playbook For Stargardt Disease With Shannon Boye, Ph.D.
- 08.20.26 -- Are Biopharma Companies Outsourcing Their Ability To Think?
- 08.19.26 -- Building A More Scalable Gene Therapy Program
- 08.19.26 -- Scaling Human-Relevant Science For Biologics Development
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
